Alastair D. Reith , PhD
Director, External Alliances & Development, R&D China at GlaxoSmithKline Pharmaceuticals R&D
Location: Stevenage, United Kingdom
Dr. Reith has broad experience in kinase signaling drug discovery in both the academic and the pharmaceutical industry sectors. He is currently director, external alliances & development R&D China at GlaxoSmithKline (GSK). He received his PhD (Biochemistry) from Imperial College London, 1988. In academia, he was a NATO postdoctoral fellow at Mount Sinai Hospital, Toronto, and assistant member at Ludwig Institute, University College London. In GlaxoSmithKline, Dr. Reith has personally championed and led several kinase inhibitor drug discovery programs, including GSK’s current LRRK2 program.
As biology chair of kinase target class, he was accountable for GSK’s global kinase inhibitor drug discovery strategy to deliver sustainable lead series - from which current late-stage clinical assets have resulted.
Dr. Reith has a proven track record in forging successful external collaborations & alliances, serves on a range of grant review panels & advisory groups in the not-for-profit sector, and is visiting professor, School of Biological Sciences, University of Reading, UK.
- Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates (2012)
- Evaluating Novel Small Molecule Inhibitors of LRRK2 to Deliver PET Ligands (2011)
- Optimising lead series of small molecule inhibitors of LRRK2 to deliver tool compounds and clinical development candidates (2009)